<DOC>
	<DOCNO>NCT02271334</DOCNO>
	<brief_summary>The objective study evaluate pharmacokinetics ( PK ) safety profile A006 , Albuterol dry powder inhaler ( DPI ) , follow single dose 110 mcg ( T1 ) 220 mcg ( T2 ) , healthy male female adult volunteer .</brief_summary>
	<brief_title>Evaluation Pharmacokinetics Safety A006 Healthy Volunteers</brief_title>
	<detailed_description>This study randomize , double evaluator-blinded , single dose , four-arm , crossover PK study eighteen ( 18 ) healthy volunteer , male female adult , 18-40 year age . All candidate screen satisfy enrollment criterion enrol study . Each study subject participate screen visit four ( 4 ) study visit one ( 1 ) randomize study treatment give visit . PK sample analyze establish LC/MS/MS method . An End-of-Study ( EOS ) safety evaluation conduct end Study Visit-4 .</detailed_description>
	<mesh_term>Albuterol</mesh_term>
	<criteria>Generally healthy , male female adult , 1840 year age Screening ; Having clinically significant respiratory , cardiovascular systemic organic illness ; Body weight ≥ 50 kg men ≥ 45 kg woman , BMI within range 18.5 30.0 kg/m2 inclusive ; Sitting blood pressure ≤ 135/90 mmHg ; Demonstrating negative HIV , HBsAg HCV test , alcohol nine panel urine drug screen test ; Demonstrating proficiency use DPI MDI able train proper use device ; Demonstrating Peak Inspiratory Flow Rate ( PIF ) within 80150 L/min ( train ) , least 2 time consecutively , maximum 5 attempt ; Having know hypersensitivity ingredient A006 Proventil® MDI ( Albuterol , sulfate , lactose , milk protein , HFA134a , oleic acid , ethanol ) . ( Subjects must able tolerate least one teaspoon milk ) ; Women childbearing potential must nonpregnant , nonlactating , practice clinically acceptable form birth control ; Having properly consent satisfied inclusion/exclusion criterion require protocol . A smoking history ≥ 5 packyears , smoke within 6 month prior Screening ; Upper respiratory tract infection within 2 week , low respiratory tract infection within 4 week , prior Screening ; Previous history asthma COPD ; Any current recent respiratory condition , per investigator discretion , might significantly affect pharmacodynamic response study drug , include cystic fibrosis , bronchiectasis , tuberculosis , emphysema , significant respiratory disease ; Concurrent clinically significant cardiovascular , hematological , renal , neurologic , hepatic , endocrine , psychiatric , malignant , illnesses opinion investigator could impact conduct , safety evaluation study ; ECG Screening Visit1 baseline express single multiple premature ventricular contraction ( PVC ) ; ECG Screening Visit1 baseline QTc reading great 450ms ; Use prohibit drug failure observe drug washout restriction ; Having clinical drug/device study donate blood last 30 day prior Screening .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Asthma</keyword>
	<keyword>Albuterol</keyword>
</DOC>